The Law Offices of Frank R. Cruz Continues Investigation of Integra Li...

Your unfiltered news center. ®

The world you see depends upon the news you get. ®

HOME

ARTS

RSS

Today's Date: June 3, 2023

Air Canada's Inaugural Amsterdam-Montreal Route Takes Off; Uplifts Sustainable Aviation Fuel in Amsterdam • Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Before Surgery and Continued as a Single Agent After Surgery • Preliminary Ongoing Results with CYT-0851 in Combination with Capecitabine or Gemcitabine in Advanced Solid Tumors Show Early Cl • Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Investigation of SentinelOne, Inc. (S) on Behalf • UNice Celebrates LGBTQ Pride Month • LYNPARZA® (olaparib) and IMFINZI® (durvalumab) combination reduced risk of disease progression or death by 37% vs. chemo • Government of Canada releases summary of actions taken to address the safety and wellbeing of Indigenous women, girls and 2SLGBT • GRAIL Presents Real-World Experience With The Galleri® Multi-Cancer Early Detection Test At 2023 ASCO Annual Meeting • San Francisco Pride Announces Headliners Hayley Kiyoko and Princess Nokia for 53rd Annual SF Pride Parade & Celebration Feat • New PATHFINDER Study Analysis Demonstrates Efficient Diagnostic Resolution Following Multi-Cancer Early Detection Testing • KEYTRUDA® (pembrolizumab) Plus Chemotherapy Significantly Improved Overall Survival Versus Chemotherapy Alone as First-Line • Promoting Diversity and Equity in Cancer Research, Women Leaders in Oncology® and Vaniam Group Announce Recipients of 2023 Y • 56 Trilogy Health Services Communities Earn 2023 AHCA/NCAL Bronze National Quality Award • High Schooler empowers Youth with Nonprofit "Unlimited Potential", raises $100,000 for Sports Medicine Research and Advocacy • Statement from Minister Hutchings on progress in support of rural Canadians • Gilead and Arcus Announce Anti-TIGIT Domvanalimab Continues to Demonstrate Consistent Improvement in Progression-Free Survival i • Exai Bio Presents New Multi-Cancer Early Detection Data at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting • Gilead and Arcus Announce Anti-TIGIT Domvanalimab Continues to Demonstrate Consistent Improvement in Progression-Free Survival i • Statement by the Prime Minister to mark four years since the publication of the final report of the National Inquiry into Missin • Bijou Ikli named new CEO by Florida Assisted Living Association

The Law Offices of Frank R. Cruz Continues Investigation of Integra LifeSciences Holdings Corporation (IART) on Behalf of Invest

LOS ANGELES , May 26 /Businesswire/ - The Law Offices of Frank R. Cruz continues its investigation of Integra LifeSciences Holdings Corporation (“Integra” or the “Company”) (NASDAQ: IART) on behalf of investors concerning the Company’s possible violations of federal securities laws.

If you are a shareholder who suffered a loss, click here to participate.

On May 23, 2023, Integra disclosed that it had initiated a recall of its SurgiMed, PriMatrix, Revize, and TissueMend products manufactured at its Boston facility as far back as March 1, 2018. The Company attributed the recall to a finding that products may have been distributed with higher levels of endotoxins than permitted by the product specifications. As a result, the Company expects to write off approximately $22 million in inventory.

On this news, Integra’s stock price fell $10.24, or 20.2%, to close at $40.48 per share on May 23, 2023, thereby injuring investors.

If you purchased Integra securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Frank R. Cruz, of The Law Offices of Frank R. Cruz, 1999 Avenue of the Stars, Suite 1100, Los Angeles, California 90067 at 310-914-5007, by email to info@frankcruzlaw.com, or visit our website at www.frankcruzlaw.com. If you inquire by email please include your mailing address, telephone number, and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.